Bear Mountain Capital’s GSK GSK Stock Holding History

Bear Mountain Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9	Closed	-$395	–	250
2025 Q3	$395	Buy	+9	New	+$352	﹤0.01%	214

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bear Mountain Capital's GSK Position: Q4 2025 in Review

Bear Mountain Capital sold out of GSK (GSK) in Q4 2025, closing a stake of 9 shares — an estimated $395 sold.

Bear Mountain Capital first reported a position in GSK in Q3 2025 and held it in 1 quarter. The position peaked at $395 in Q3 2025. 997 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Bear Mountain Capital reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Bear Mountain Capital sold 9 GSK shares in Q4 2025, an estimated $395.
Bear Mountain Capital first reported a position in GSK in Q3 2025 and held it in 1 quarter.
Bear Mountain Capital's GSK position peaked at $395 in Q3 2025.
997 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Bear Mountain Capital's 13F filing for Q4 2025, filed 22 Jan 2026.